PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B

The PAM50 classifier is widely used for breast tumor intrinsic subtyping based on gene expression. Clinical subtyping, however, is based on immunohistochemistry assays of 3–4 biomarkers. Subtype calls by these two methods do not completely match even on comparable subtypes. Nevertheless, the estroge...

Descripción completa

Detalles Bibliográficos
Autores principales: Raj-Kumar, Praveen-Kumar, Liu, Jianfang, Hooke, Jeffrey A., Kovatich, Albert J., Kvecher, Leonid, Shriver, Craig D., Hu, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538748/
https://www.ncbi.nlm.nih.gov/pubmed/31138829
http://dx.doi.org/10.1038/s41598-019-44339-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538748/
https://www.ncbi.nlm.nih.gov/pubmed/31138829
http://dx.doi.org/10.1038/s41598-019-44339-4

Ejemplares similares